Clinical Trials Logo

Clinical Trial Summary

Chimeric antigen receptor T cells (CAR-T cells) have been developed to treat relapsed and refractory hematological malignancies with promising outcome in patients with very poor prognosis. The purpose of this clinical study is to produce the CD19[cluster of differentiation antigen 19] CAR-T (SNUH-CD19-CAR-T) at the investigational site and to evaluate safety and efficacy of SNUH-CD19-CAR-T in children and adolescent with relapsed/refractory B-cell acute lymphoblastic leukemia.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05210907
Study type Interventional
Source Seoul National University Hospital
Contact Hyoungjin Kang, PhD
Phone +82-2-2072-3304
Email [email protected]
Status Recruiting
Phase Phase 1
Start date February 15, 2022
Completion date August 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03671460 - CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL. Phase 1
Recruiting NCT05016947 - Venetoclax Plus Inotuzumab for B-ALL Phase 1
Suspended NCT01974479 - Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia Phase 1
Completed NCT00289562 - Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT04191941 - Treatment of Hematological Malignancy With Novel CAR-T Cells. Early Phase 1
Recruiting NCT05333302 - Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma Phase 1
Recruiting NCT04129099 - A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Early Phase 1
Not yet recruiting NCT05082519 - Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL Phase 2
Recruiting NCT04150497 - Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) Phase 1
Recruiting NCT03281551 - Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma Phase 1
Recruiting NCT05379647 - Natural Killer (NK) Cell Therapy for B-Cell Malignancies Phase 1
Withdrawn NCT04156659 - Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL Phase 2
Recruiting NCT04094311 - Study of Out of Specification for Tisagenlecleucel Phase 3
Completed NCT01207388 - Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Phase 2
Active, not recruiting NCT03467256 - CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL Phase 1/Phase 2
Recruiting NCT03962465 - Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Younger Adults With Relapsed/Refractory B-cell ALL Phase 1
Terminated NCT04844086 - RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies Phase 1
Not yet recruiting NCT04595162 - A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL Phase 1
Recruiting NCT04289220 - Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT03666000 - Dose-escalation, Dose-expansion Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL Phase 1/Phase 2